Invention Grant
US08541553B2 Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
失效
针对黑素瘤相关内源性逆转录病毒（MERV）包膜糖蛋白特异的抗体
- Patent Title: Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
- Patent Title (中): 针对黑素瘤相关内源性逆转录病毒（MERV）包膜糖蛋白特异的抗体
-
Application No.: US12601780Application Date: 2008-05-23
-
Publication No.: US08541553B2Publication Date: 2013-09-24
- Inventor: Johannes Humer , Bernd Mayer , Thomas Muster , Andrea Waltenberger
- Applicant: Johannes Humer , Bernd Mayer , Thomas Muster , Andrea Waltenberger
- Applicant Address: CH Glattpark (Opfikon)
- Assignee: Baxter Healthcare SA
- Current Assignee: Baxter Healthcare SA
- Current Assignee Address: CH Glattpark (Opfikon)
- Agency: Loza & Loza, LLP
- Agent Michael Fedrick
- Priority: ATA830/2007 20070524; ATA160/2008 20080201
- International Application: PCT/EP2008/056359 WO 20080523
- International Announcement: WO2008/142157 WO 20081127
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C12N5/07 ; A61K39/42 ; A61K39/21
Abstract:
The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.
Public/Granted literature
- US20100136518A1 ANTIBODIES USEFUL FOR THERAPY AND DIAGNOSIS OF CANCER Public/Granted day:2010-06-03
Information query
